Pharmaceuticals company Acutaas Chemicals announced Q2FY26 results Revenue from operations for Q2FY26 grew by 24.1% YoY to Rs 3,062 million. The gross margin for the quarter improved to 55.8% up 1,232 bps YoY. EBITDA for the quarter came at Rs 953 million up 94.8% YoY. EBITDA margin for the quarter was at 31.1% as compared to 19.8% in Q2FY25. PAT for the quarter was Rs 719 million up 91.3% as compared to PAT of Rs 376 million in Q2FY25. The PAT margin for the quarter was at 23.5% up 824 bps YoY. Export for the quarter at 76%; domestic business at 24%. Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals, said: “Our focus has always been on building a long-term, sustainable business rather than chasing short-term opportunities. This disciplined approach is now yielding tangible results as we strengthen global partnerships and expand into new growth verticals such as Battery Chemicals and Semiconductors. In Q2FY26, our revenue grew by 24.1% YoY to Rs 3,062 million, driven by strong performance in Advanced Pharmaceutical Intermediates and stable contributions from Specialty Chemicals. We remain confident of delivering around 25% revenue growth for the full year, backed by a resilient business foundation and clear strategic direction” Result PDF
Pharmaceuticals company Acutaas Chemicals announced Q1FY26 results Revenue from operations for Q1FY26 grew by 17.3% YoY to Rs 2,072 million The gross margin for the quarter improved to 53.2% up 1,117 bps YoY EBITDA for the quarter came at Rs 509 million up 72.4% YoY EBITDA margin for the quarter was at 24.6% as compared to 16.7% in Q1FY25 PAT for the quarter was Rs 440 million up 199.6% as compared to PAT of Rs 147 million in Q1FY25 The PAT margin for the quarter was at 21.2% up 1,292 bps YoY Export for the quarter at 60%; domestic business at 40% Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am happy to share that we’ve had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality. I am happy to announce that we have entered into a joint venture in South Korea which brings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across COMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins.” Result PDF
Pharmaceuticals company Ami Organics announced Q4FY25 results Revenue from operations for Q4FY25 grew by 37.1% YoY to Rs 3,085 million. The gross margin for the quarter improved to 47.3% up 734 bps YoY and 108 bps QoQ. EBITDA for the quarter came at Rs 850 million up 96.8% YoY compared to Rs 432 million in Q4FY24. EBITDA margin for the quarter was at 27.5% as compared to 19.2% in Q4FY24. PAT for the quarter was Rs 627 million up 144.2% as compared to PAT of Rs 257 million in Q4FY24. The PAT margin for the quarter was at 20.3% up 892 bps YoY and 380 bps QoQ. Export for the quarter at 74%; domestic business at 26%. Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenue a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions. As we embark on an exciting new phase of growth, we are embracing a bold, future-focused brand identity that aligns with our vision to lead as a diversified specialty chemicals company, serving next-generation industries with a steadfast commitment to sustainability. To reflect this ambition, we are transitioning from “Ami Organics Limited” to “Acutaas Chemicals Limited”. Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.” Result PDF
